More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.02B
EPS
0.05
P/E ratio
--
Price to sales
8.48
Dividend yield
--
Beta
0.703756
Previous close
$23.04
Today's open
$22.62
Day's range
$20.95 - $22.62
52 week range
$14.19 - $36.50
show more
CEO
David Dean Halbert
Employees
1846
Headquarters
Irving, TX
Exchange
Nasdaq Global Select
Shares outstanding
286784504
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
BTSG vs. CAI: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either BrightSpring Health Services, Inc. (BTSG) or Caris Life Sciences,?Inc. (CAI). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research • Nov 9, 2026

Caris Life Sciences Q3 Earnings Call Highlights
Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new tests.
MarketBeat • Nov 5, 2026

Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.
PRNewsWire • Nov 4, 2026

Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates
Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern technology can measure nearly every aspect of athletic performance, the same level of intelligence can be applied to helping people find early stage cancer – when treatment is most effective.
PRNewsWire • Oct 19, 2026

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
PRNewsWire • Oct 15, 2026

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.
PRNewsWire • Oct 14, 2026

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
Investors Business Daily • Oct 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Caris Life Sciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.